Details of the Drug

General Information of Drug (ID: DMKMJHE)

Drug Name
Cemiplimab
Synonyms REGN2810; REGN-2810; REGN 2810
Indication
Disease Entry ICD 11 Status REF
Cutaneous squamous cell carcinoma 2C30 Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
L01FF06: Cemiplimab
L01FF: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 166 mg/L []
Clearance
The clearance of drug is 0.32 L/day []
Half-life
The concentration or amount of drug in body reduced by one-half in 19 days []
Vd
The volume of distribution (Vd) of drug is 5.3 L []
Cross-matching ID
UNII
6QVL057INT
DrugBank ID
DB14707
TTD ID
D0KG4Q

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Modulator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cutaneous squamous cell carcinoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.